New Delhi: The pharmaceutical company Zydus Cadila has sought permission from the Controller General of Indian Drugs (DCGI) to use the hepatitis drug Pegylated Interferon Alpha-2B in the treatment of COVID-19. Zydus Cadila said in a statement on Monday that a Phase III clinical trial of Pegylated Interferon Alpha 2B has given encouraging results regarding the treatment of Covid-19 with this drug.
The company sells this drug under the brand name ‘Pegihep’. The company said that the initial results that have been revealed show that initially, the patient of Covid-19 recover more quickly with its use. Also, it does not cause any problems to the patient.
Zydus Cadila slashes generic Covid-19 drug prices
Earlier in the month of March, Zydus Cadila announced a significant reduction in the prices of its generic version of the ramadasivir drug. After which the company has reduced the price of a generic version of the drug Covid-19 to Rs 899 per bottle (100mg). The company introduced Remdac in the country in August 2019. At that time, the price of a 100 mg bottle of this medicine given as an injection was Rs 2800.
Zydus Cadila said in his statement on 24 March that Remadecivir is an important drug in the treatment of Covid-19. This step will help the patients a lot during such a difficult time.
